Skip to main content
BioMaxima S.A. logo

BioMaxima S.A. — Investor Relations & Filings

Ticker · BMX ISIN · PLBIOMX00015 LEI · 2594007GAALFMXP4YB89 WAR Manufacturing
Open in API
Filings indexed 616 across all filing types
Latest filing 2025-06-05 Board/Management Inform…
Country PL Poland
Listing WAR BMX

About BioMaxima S.A.

https://www.biomaxima.com/

BioMaxima S.A. is a manufacturer specializing in in-vitro diagnostics. The company's primary activities include the development and production of a wide range of products for laboratory diagnostics, with a focus on clinical microbiology. Key product categories include microbiological media, various diagnostic reagents, and specialized laboratory equipment. In addition to its manufacturing operations, BioMaxima also serves as a distributor for products from other global diagnostics firms. The company is actively involved in product innovation, including the development of Minimum Inhibitory Concentration (MIC) tests for antibiotic susceptibility testing.

Recent filings

Filing Released Lang Actions
Zawiadomienie od osoby zobowiązanej - Content (PL)
Board/Management Information Classification · 99% confidence The document text is extremely short (131 characters) and states that the Management Board (Zarząd) of BioMaxima S.A. is making a notification received from the CEO public. This structure strongly suggests a brief regulatory disclosure or announcement, rather than a comprehensive report (like 10-K, AR, or IR). Since it is a general announcement of information received and made public, and it doesn't fit specific categories like Director's Dealing (DIRS), Dividend (DIV), or Major Shareholding (MRQ), the most appropriate fallback category for a general regulatory announcement is Regulatory Filings (RNS).
2025-06-05 Polish
Skonsolidowane sprawozdanie finansowe wraz z jednostkową informacją finansową
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for BioMaxima S.A. for the first quarter of 2025. It includes a letter from the CEO, consolidated financial statements (balance sheet, income statement, cash flow), and detailed notes to the financial statements. It is not an announcement of a report, but the report itself, containing substantive financial data. Therefore, it is classified as an Interim / Quarterly Report. Q1 2025
2025-05-30 Polish
Sprawodanie o wynagrodzeniach
Remuneration Information Classification · 98% confidence The document is titled 'Sprawozdanie Rady Nadzorczej o wynagrodzeniach Członków Zarządu i Rady Nadzorczej za 2024 r.' (Report of the Supervisory Board on the remuneration of the Management Board and Supervisory Board Members for 2024). It explicitly references Polish regulations concerning public offerings and public companies (art. 90g ustawy z dnia 29 lipca 2005 roku o ofercie publicznej...). The content details the fixed and variable remuneration, non-cash benefits for the Management Board and Supervisory Board members for the year 2024, and confirms compliance with the company's remuneration policy. This content directly aligns with the definition of a Remuneration Information report, which corresponds to the DEF 14A code in the provided schema, even though the document is Polish and not a US SEC DEF 14A filing, the subject matter is identical.
2025-05-29 Polish
Sprawozdanie Rady Nadzorczej
Audit Report / Information Classification · 98% confidence The document is titled "Sprawozdanie Rady Nadzorczej za 2024 r." (Supervisory Board Report for 2024) and details the activities of the Supervisory Board, including its assessment of the Financial Statements, Management Report, and the proposal for profit distribution for the fiscal year 2024. This document is a formal report prepared by the Supervisory Board, mandated by Polish commercial code (Kodeks spółek handlowych, art. 382 § 3). While it reviews the Annual Financial Statements (which would typically be part of a 10-K equivalent), the document itself is the Supervisory Board's specific report on its oversight activities and review findings, not the primary financial statements or the full annual report (10-K). It is a comprehensive report covering the entire year, but it is distinct from the primary financial filing. Given the options, it most closely aligns with a comprehensive annual review document prepared by a governing body. Since there isn't a specific 'Supervisory Board Report' code, and it is a comprehensive annual report covering financial review, it is closest to an Annual Report (10-K) in scope, but since it is explicitly the Supervisory Board's assessment, and not the full statutory annual report itself, it is often categorized under general Audit/Review reports or sometimes as a specific type of Annual Report depending on jurisdiction. However, in the context of the provided definitions, it is a detailed report covering the year's activities and financial review, making it more substantial than an Audit Report (AR) which is usually standalone audit opinions. Since it covers the entire year's performance review by the board, it functions similarly to the narrative/oversight section of an Annual Report, but the core content is the Board's assessment. Given the Polish context, this type of report is often filed alongside the annual financial statements. Since it is a full report (25k+ characters) and not just an announcement, and it covers the entire year's financial review, it is best classified as an Annual Report (10-K) equivalent, or potentially an Audit Report (AR) due to the heavy focus on auditing the financial statements, but the scope is broader (board activities, risk management, etc.). I will lean towards AR as it is explicitly focused on the review/audit function performed by the Supervisory Board/Audit Committee over the financial results, which aligns well with the definition of 'Audit Report / Information'. FY 2024
2025-05-29 Polish
Zawiadomienie o zwołaniu WZ wraz z projektami uchwał
AGM Information Classification · 100% confidence The document is explicitly titled "Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia BioMaxima Spółka Akcyjna" (Announcement of the convening of the Annual General Meeting of BioMaxima S.A.). It details the date (June 25, 2025), location, and the proposed agenda (porządek obrad), which includes approving the 2024 financial statements and granting discharge (absolutorium) to management and the supervisory board. The text also covers shareholder rights regarding agenda items and voting procedures. This content perfectly matches the definition of materials related to an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2025-05-29 Polish
Ogłoszenie o zwołaniu ZWZ BioMaxima SA wraz z projektami uchwał - Content (PL)
AGM Information Classification · 98% confidence The document text is very short (239 characters) and explicitly states that the Management Board ('Zarząd') is making public an announcement ('ogłoszenie') regarding the convening of the Annual General Meeting ('Zwyczajnego Walnego Zgromadzenia') along with draft resolutions and previously unpublished documents for discussion. This structure—announcing the meeting and associated materials—strongly suggests a filing related to the AGM. Given the content focuses on the convening of the AGM and related materials, the most appropriate classification is AGM Information (AGM-R). It is not a general regulatory filing (RNS) because it is highly specific to the AGM.
2025-05-29 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.